Recent machine-extracted executive movements from SEC 8-K Item 5.02 filings, source-linked. Every card cites the SEC source.
Showing 7451–7500 of 75483
John Vong, the Company’s current Chief Accounting Officer and principal accounting officer, will transition to a new role at the Company and will no longer serve as the principal accounting officer as of the Effective Date.
On March 24, 2025, Briley Brisendine, the Company’s Executive Vice President, General Counsel and Secretary, notified the Company of his intent to resign from the Company.
Cathy McCarthy would not stand for re-election as a Class III director on the Board of Directors of the Company (the “Board”) upon the completion of her current term, which expires at the Company’s 2025 Annual Meeting of Stockholders
On March 28, 2025, Werner Cautreels notified Traws Pharma, Inc. (the Company”) of his decision to retire and resign from his role as Chief Executive Officer of the Company, effective as of the close of business on the day that the Company files its Annual Report on Form 10-K for its 2024 fiscal year
Effective as of the Termination Date, the Board appointed Iain Dukes to serve as the Company’s Interim Chief Executive Officer.
On March 25, 2025, the Board of Directors (the “Board”) of Rezolute, Inc. (the “Company”) upon the recommendation of the Company’s nominating and corporate governance committee elected Erik Harris to the Board, effective March 25, 2025
On March 27, 2025, the Board appointed Thomas Hansen as interim Chief Financial Officer
On March 24, 2025, Gerard Waldt notified the Board of Trustees (the “Board”) of T. Rowe Price OHA Select Private Credit Fund (the “Company”) of his resignation as the Company’s Chief Financial Officer
On March 24, 2025, Gerard Waldt notified the Board of Managers (the “Board”) of OHA Senior Private Lending Fund (U), LLC (the “Company”) of his resignation as the Company’s Chief Financial Officer in order to pursue other professional opportunities.
On March 27, 2025, the Board appointed Thomas Hansen as interim Chief Financial Officer of the Company effective as of the close of business on April 28, 2025.
The Board approved the nomination of Messrs. Jonathan R. Liebman and Jordan Moelis as candidates for election to Class II of the Board
The Board approved the nomination of Messrs. Jonathan R. Liebman and Jordan Moelis as candidates for election to Class II of the Board
Matthew Winkler resigned from the Board, effective immediately prior to the shareholders meeting to be held in 2025
In connection with the consummation of the Merger, James R. Scapa, Matthew Brown and Stephanie Buckner ceased to serve as the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer, respectively, of the Surviving Corporation.
In connection with the consummation of the Merger, James R. Scapa, Matthew Brown and Stephanie Buckner ceased to serve as the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer, respectively, of the Surviving Corporation.
Immediately after the consummation of the Merger, Anthony L. Hemmelgarn and Timo Nentwich have been appointed as the Chief Executive Officer and Chief Financial Officer, respectively, of the Surviving Corporation.
In connection with the consummation of the Merger, James R. Scapa, Matthew Brown and Stephanie Buckner ceased to serve as the Chief Executive Officer, Chief Financial Officer and Chief Operating Officer, respectively, of the Surviving Corporation.
Immediately after the consummation of the Merger, Anthony L. Hemmelgarn and Timo Nentwich have been appointed as the Chief Executive Officer and Chief Financial Officer, respectively, of the Surviving Corporation.
On March 25, 2025, Isabelle F. Geday notified the board of directors (the “Board”) of Arteris, Inc. (the “Company”) of her decision to resign from the Board, effective as of March 27, 2025.
On March 28, 2025, our Board of Directors increased the size of the Board of Directors to six members and elected Darius G. Nevin as a director for a term expiring at our 2025 annual meeting of shareholders.
On March 24, 2025, Mr. Carl E. Vogel, a director elected by holders of the Class A Common Stock of Sphere Entertainment Co. (the “Company”), notified the Company of his intention not to stand for re-election when his term expires at the Company’s upcoming 2025 Annual Meeting of Stockholders anticipated to be held on June 4, 2025 (the “Annual Meeting”).
Pursuant to the Prigge Separation Agreement, effective as of March 31, 2025 (the "Transition Date"), Ms. Prigge will continue to serve at 3 ⁄ 4 full time as the Company’s Executive Vice President, Chief Service Delivery Officer during the period commencing on the Transition Date and ending on June 6, 2025 (such period, the "Transition Period").
On March 26, 2025, the Board of Directors (the “Board”) of Blue Owl Capital Inc. (the “Company”) appointed Jennifer Brouse as a member of the Board, filling the vacancy from the prior resignation of Sean Ward.
On March 27, 2025, David L. Herzog, a director of MetLife, Inc. (the “Company”), notified the Company’s Board of Directors (the “Board”) of his decision to resign from the Board, effective May 1, 2025, and not to stand for re-election at the Company’s 2025 annual meeting of shareholders.
On March 26, 2025, EnerSys separated employment with Joern Tinnemeyer, EnerSys’ Senior Vice President and Chief Technology Officer.
L. Michelle Moore's appointment as a member of the Tennessee Valley Authority Board of Directors ended March 27, 2025, at the direction of the President of the United States.
On March 24, 2025, William W. Stead, M.D. notified HealthStream, Inc. (the “Company”) that he has decided not to stand for re-election to the Company’s Board of Directors (the “Board”) as a Class I director at the Company’s annual meeting of stockholders and to retire from service on the Board effective concurrently with this annual meeting.
On March 27, 2025, Dr. Madaus notified the Board of his intention to resign from the Board and each committee of the Board on which he serves no later than the date of the Company's 2025 annual meeting of stockholders
On March 24, 2025, the board of directors (the "Board") of Quanterix Corporation (the "Company") appointed William P. Donnelly to serve as Chairman of the Board, effective immediately.
On March 28, 2025, Dr. Robert Hariri informed BioVie Inc. (the “Company”) of his decision to resign from the Board of Directors of the Company (the “Board”), effective as of such date.
On March 26, 2025, Christopher Merritt, a member of the Board of Directors (the "Board") of DigitalOcean Holdings, Inc. (the "Company"), notified the Company of his intention not to stand for reelection at the Company's 2025 Annual Meeting of Stockholders (the "Annual Meeting").
On March 27, 2025, Julie A. Schertell, a member of the Board of Directors (the “Board”) of Ingersoll Rand Inc. (the “Company”) notified the Board of her intention to resign as a member of the Board and as a member of the Nominating and Corporate Governance Committee and the Sustainability Committee of the Board., effective on March 27, 2025.
On March 24, 2025, Ms. Stacy L. Dillow, Executive Vice President and Chief Human Resources Officer of Fluor Corporation (the “Corporation”), notified the Corporation of her decision to resign from her position, effective April 11, 2025.
the Board has nominated Monty Moran and Dawn Ostroff as new independent directors
Sweetgreen, Inc. (the “Company”) announced that Youngme Moon and Valerie Jarrett will not stand for re-election as directors of the Company at the 2025 annual meeting of stockholders
Sweetgreen, Inc. (the “Company”) announced that Youngme Moon and Valerie Jarrett will not stand for re-election as directors of the Company at the 2025 annual meeting of stockholders
the Board has nominated Monty Moran and Dawn Ostroff as new independent directors
On March 21, 2025, Joseph Mohr resigned from his position as the Board of Directors (the “Board”) of Syntec Optics Holdings, Inc. (the “Company”).
On March 25, 2025, Andrew Munk, Chief Accounting Officer, informed Samsara Inc. (the “Company”) that he plans to retire and will step down from his position as Chief Accounting Officer, effective as of the end of the day on April 8, 2025.
In connection with Mr. Munk’s retirement, Dominic Phillips, the Company’s Chief Financial Officer, will assume the responsibilities of principal accounting officer on an interim basis, effective April 9, 2025, while the Company searches for a replacement.
On March 25, 2025, in connection with the Chaintrade transaction, Paul Couture was terminated from his position as Chief Technology Officer of the Company.
John Power, the former President and CEO of the Company resigned as President and CEO
Koby Kushner was appointed to serve as President and CEO of the Company
On March 26, 2025, the board of directors of Southland Holdings, Inc. (the “Company”) appointed Rudy Renda as a Class II director to fill a vacant seat
Mr. Stagno will report to Tim O’Brien, the Company's Chief Financial Officer, who previously served as the Company’s Principal Accounting Officer and Principal Financial Officer and will continue to serve as the Company's Principal Financial Officer.
appointed Christopher Stagno, age 50, as the Company’s Group Vice President, Chief Accounting Officer (Principal Accounting Officer), effective April 21, 2025.
On March 28, 2025, Ms. Ricki Fairley, a director of Xeris Biopharma Holdings, Inc. (the “Company”), notified the Company of her decision to resign from the Board of Directors (the “Board”) of the Company, effective as of March 28, 2025.
On March 28, 2025, the Board appointed Mr. James Brady to the Company’s Board, effective on such date.
On March 28, 2025, Mr. John Schmid informed the Board of his decision to not stand for reelection as a director at the Company’s 2025 annual meeting of stockholders (the “2025 Annual Meeting”).
Effective March 26, 2025, Gregory J. Hayes was elected to the Board of Directors (the “Board”) of Becton, Dickinson and Company (“BD”).
Recent executive movements from 8-K Item 5.02 filings, source-linked. Cards are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.